Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

Almost all patients with multiple myeloma (MM) will eventually develop disease that has
relapsed with or become refractory to available treatments and will require additional …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–
directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or …

Background Belantamab mafodotin had single-agent activity in patients with relapsed or
refractory multiple myeloma, a finding that supports further evaluation of the agent in …

Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …

CD38 is a transmembrane glycoprotein that functions both as a receptor and an
ectoenzyme, playing key roles in the regulation of calcium signaling and migration of …

CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib,
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …

The amount of unfolded proteins is increased in cancer cells, leading to endoplasmic
reticulum (ER) stress. Therefore, cancer cells are sensitive to drugs capable of further …

Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …

The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …